William Blair Equities Analysts Decrease Earnings Estimates for Dynavax Technologies Co. (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities research analysts at William Blair decreased their FY2020 earnings per share estimates for Dynavax Technologies in a research report issued to clients and investors on Tuesday, December 3rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of ($1.10) per share for the year, down from their prior estimate of ($1.09). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Dynavax Technologies’ Q4 2020 earnings at ($0.25) EPS, FY2021 earnings at ($0.68) EPS, FY2022 earnings at ($0.51) EPS and FY2023 earnings at ($0.30) EPS.

DVAX has been the topic of several other research reports. BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Dynavax Technologies currently has a consensus rating of “Buy” and an average price target of $12.63.

Shares of DVAX stock opened at $5.70 on Friday. The company has a quick ratio of 4.09, a current ratio of 4.94 and a debt-to-equity ratio of 5.48. The firm has a market cap of $486.42 million, a P/E ratio of -2.23 and a beta of 0.56. The company has a 50 day moving average of $5.29 and a 200-day moving average of $4.38. Dynavax Technologies has a 12-month low of $2.60 and a 12-month high of $12.42.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.10). Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The company had revenue of $10.58 million during the quarter, compared to the consensus estimate of $10.31 million. During the same period in the prior year, the firm posted ($0.65) EPS. The business’s revenue was up 624.7% on a year-over-year basis.

Large investors have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Dynavax Technologies by 95.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,402 shares during the period. Bank of Montreal Can increased its position in shares of Dynavax Technologies by 148.4% during the second quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,445 shares during the period. Wedbush Securities Inc. bought a new stake in shares of Dynavax Technologies during the second quarter valued at about $42,000. Ingalls & Snyder LLC purchased a new stake in shares of Dynavax Technologies in the third quarter worth about $52,000. Finally, M&T Bank Corp lifted its holdings in shares of Dynavax Technologies by 29.5% in the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 3,116 shares in the last quarter. Hedge funds and other institutional investors own 82.36% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

See Also: What is the Nikkei 225 index?    

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit